First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

NCT05348889 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's Research and Development strategy adjustment

Conditions

Non-Hodgkin's Lymphoma (disorder)
Acute Lymphoid Leukemia, Disease (disorder)

Interventions

DRUG: 1A46 Injection

Sponsor

Chimagen Biosciences, Ltd